evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

21 questions · 27 findings · 4 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 3.7%GRADE not reported 0 · 0%Very low 7 · 25.9%Low 6 · 22.2%Moderate 8 · 29.6%High 5 · 18.5%

Chemotherapy vs chemotherapy alone

Progression‐free survival (PSF) · advanced gastric adenocarcinoma

Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).

3 findings from 1 review

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).

1 finding from 1 review

Chemmotherapy combined with biological therapy vs chemotherapy alone

Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

It is very uncertain whether chemmotherapy combined with biological therapy changes progression‐free survival compared with chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).

1 finding from 1 review

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table: chemotherapy or targeted therapy agent(s)… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes progression‐free survival compared with BSC (very low certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Progression‐free survival · palliative participants with AC of the esophagus

It is very uncertain whether summary of findings table (subcomparison 5): chemotherapy or… changes progression‐free survival compared with control intervention alone (very low certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Progression‐free survival · palliative participants with SCC of the esophagus

It is very uncertain whether summary of findings table (subcomparison 6): chemotherapy or… changes progression‐free survival compared with control intervention alone (very low certainty).

1 finding from 1 review

Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine)

Progression‐free survival · people with advanced gastric cancer

Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).

1 finding from 1 review

Docetaxel vs non‐docetaxel‐containing regimens

Progression‐free survival (PSF) · people with advanced gastric cancer

It is very uncertain whether docetaxel changes progression‐free survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (very low certainty).

3 findings from 1 review